Sumitomo Mitsui Trust Holdings Inc. Buys 99,511 Shares of Twist Bioscience Co. (NASDAQ:TWST)

Sumitomo Mitsui Trust Holdings Inc. increased its holdings in shares of Twist Bioscience Co. (NASDAQ:TWST - Free Report) by 2.9% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,583,443 shares of the company's stock after buying an additional 99,511 shares during the period. Sumitomo Mitsui Trust Holdings Inc. owned about 6.20% of Twist Bioscience worth $132,086,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in TWST. Captrust Financial Advisors boosted its position in Twist Bioscience by 101.3% during the 2nd quarter. Captrust Financial Advisors now owns 759 shares of the company's stock worth $27,000 after buying an additional 382 shares during the period. Federated Hermes Inc. acquired a new position in shares of Twist Bioscience in the 3rd quarter worth approximately $29,000. China Universal Asset Management Co. Ltd. lifted its position in shares of Twist Bioscience by 96.3% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,470 shares of the company's stock worth $30,000 after purchasing an additional 721 shares during the period. US Bancorp DE lifted its position in shares of Twist Bioscience by 257.1% in the 2nd quarter. US Bancorp DE now owns 2,050 shares of the company's stock worth $42,000 after purchasing an additional 1,476 shares during the period. Finally, Comerica Bank acquired a new position in shares of Twist Bioscience in the 3rd quarter worth approximately $46,000.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on TWST shares. Scotiabank boosted their price target on shares of Twist Bioscience from $30.00 to $43.00 and gave the stock a "sector outperform" rating in a research report on Monday, February 5th. The Goldman Sachs Group upgraded shares of Twist Bioscience from a "neutral" rating to a "buy" rating and boosted their price target for the stock from $25.00 to $45.00 in a research report on Wednesday, January 17th. Finally, Barclays dropped their price target on shares of Twist Bioscience from $45.00 to $40.00 and set an "overweight" rating on the stock in a research report on Wednesday, April 10th.

Twist Bioscience Price Performance

Shares of Twist Bioscience stock traded down $0.63 during trading on Tuesday, reaching $28.61. 870,953 shares of the company traded hands, compared to its average volume of 919,512. Twist Bioscience Co. has a 1-year low of $11.46 and a 1-year high of $43.21. The company has a 50 day moving average price of $35.98 and a 200-day moving average price of $29.95. The firm has a market capitalization of $1.65 billion, a PE ratio of -7.93 and a beta of 1.62.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last released its earnings results on Friday, February 2nd. The company reported ($0.75) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.78) by $0.03. The company had revenue of $71.50 million for the quarter, compared to the consensus estimate of $67.59 million. Twist Bioscience had a negative net margin of 78.44% and a negative return on equity of 32.16%. Twist Bioscience's quarterly revenue was up 31.8% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.74) EPS. Equities research analysts expect that Twist Bioscience Co. will post -3.17 earnings per share for the current year.

Insider Transactions at Twist Bioscience

In other news, CEO Emily M. Leproust sold 1,132 shares of the company's stock in a transaction on Tuesday, April 2nd. The shares were sold at an average price of $32.74, for a total value of $37,061.68. Following the completion of the sale, the chief executive officer now owns 514,149 shares in the company, valued at approximately $16,833,238.26. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In related news, CEO Emily M. Leproust sold 1,487 shares of the stock in a transaction dated Wednesday, March 6th. The shares were sold at an average price of $37.43, for a total transaction of $55,658.41. Following the completion of the transaction, the chief executive officer now owns 516,409 shares in the company, valued at $19,329,188.87. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Emily M. Leproust sold 1,132 shares of the stock in a transaction dated Tuesday, April 2nd. The shares were sold at an average price of $32.74, for a total transaction of $37,061.68. Following the transaction, the chief executive officer now owns 514,149 shares of the company's stock, valued at approximately $16,833,238.26. The disclosure for this sale can be found here. Insiders sold a total of 11,037 shares of company stock worth $384,092 in the last quarter. 3.92% of the stock is currently owned by corporate insiders.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.